Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Erythrocyte aggregation and vascular pathology].

M Delamaire1, F Durand

  • 1Centre régional de transfusion sanguine, Rennes.

Journal Des Maladies Vasculaires
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of severe acute alcoholic hepatitis in France: results of a national survey: R1.

Clinics and research in hepatology and gastroenterology·2026
Same author

Seed morphometrics unravels the evolutionary history of grapevine in France.

Scientific reports·2024
Same author

Practical model to identify liver transplant recipients at low risk of postoperative haemorrhage, bile leakage and ascites.

BJS open·2021
Same author

Acute and Post-Traumatic Stress Disorders: A biased nervous system.

Revue neurologique·2020
Same author

Treatment of sleep apnea by ENT specialists during the COVID-19 pandemic.

European annals of otorhinolaryngology, head and neck diseases·2020
Same author

Global Transplantation COVID Report March 2020.

Transplantation·2020

Erythrocyte aggregation significantly impacts vascular diseases by increasing blood viscosity in veins and contributing to arterial stenosis. Treatments focus on improving blood flow and red blood cell properties.

Area of Science:

  • Hematology
  • Vascular Biology
  • Hemodynamics

Context:

  • Erythrocyte aggregation is a critical factor in both venous and arterial vascular diseases.
  • Low blood flow in veins promotes erythrocyte aggregation, leading to hyperviscosity and stasis.
  • Arterial diseases involve erythrocyte hyperaggregation due to risk factors like smoking, hypertension, and diabetes, contributing to stenosis.

Purpose:

  • To elucidate the role of erythrocyte aggregation in vascular pathologies.
  • To explore the mechanisms linking erythrocyte aggregation to venous stasis and arterial stenosis.
  • To review treatment strategies for hemorheological disorders associated with erythrocyte aggregation.

Summary:

  • Erythrocyte aggregation contributes to blood hyperviscosity and stasis in venous diseases.

Related Experiment Videos

  • In arterial diseases, erythrocyte hyperaggregation exacerbates stenosis, posing severe health risks.
  • Treatment approaches include hemodilution and agents that reduce fibrinogen or enhance red blood cell deformability.

    • Impact:

    • Understanding erythrocyte aggregation is key to managing vascular diseases.
    • Targeting hemorheological disorders offers therapeutic potential for vascular conditions.
    • Improved red blood cell properties and reduced viscosity can mitigate disease progression and consequences.